Rapport Therapeutics, Inc. (RAPP)

NASDAQ: RAPP · IEX Real-Time Price · USD
24.30
+1.25 (5.42%)
At close: Jun 14, 2024, 4:00 PM
25.32
+1.02 (4.20%)
After-hours: Jun 14, 2024, 7:55 PM EDT
5.42%
Market Cap 859.65M
Revenue (ttm) n/a
Net Income (ttm) -51.31M
Shares Out 35.38M
EPS (ttm) -1.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 365,001
Open 22.55
Previous Close 23.05
Day's Range 21.30 - 25.77
52-Week Range 18.00 - 27.11
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Aug 10, 2024

About RAPP

Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (“CNS”) disorders. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor associated proteins (“RAPs”), the latter of which play crucial roles in regulating receptor expression and function. RAP-219, our most advanced product candidate, is designed to achieve neuroanatomical specificity thro... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 7, 2024
Employees 58
Stock Exchange NASDAQ
Ticker Symbol RAPP
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small...

2 days ago - GlobeNewsWire

J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut

Shares of Rapport Therapeutics , backed by Johnson & Johnson's venture capital arm, rose nearly 6% in their market debut on Friday, valuing the early stage therapy developer at $636.8 million.

Other symbols: JNJ
7 days ago - Reuters

J&J-backed Rapport Therapeutics raises $136 mln in US IPO

Rapport Therapeutics said on Thursday that it has raised $136 million in its initial public offering in the United States at a valuation of about $601.4 million.

Other symbols: JNJ
8 days ago - Reuters

Rapport Therapeutics Announces Pricing of Initial Public Offering

BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small...

8 days ago - GlobeNewsWire

J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO

Rapport Therapeutics is targeting a valuation of about $637 million in its initial public offering in the United States, as the biopharmaceutical company joins a slew of firms looking to list their sh...

Other symbols: JNJ
11 days ago - Reuters

J&J-backed startup Rapport files for US IPO

Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson , filed for an initial public offering in the United States on Friday.

4 weeks ago - Reuters

CNS disorder biotech Rapport Therapeutics files for a $100 million IPO

Rapport Therapeutics, a Phase 2-ready biotech developing small molecule therapies for CNS disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

4 weeks ago - Renaissance Capital

Rapport Therapeutics IPO Registration Document (S-1)

Rapport Therapeutics has filed to go public with an IPO on the NASDAQ.

4 weeks ago - SEC